Bildkälla: Stockfoto

Episurf Medical Q2: Changed strategy - Redeye

Redeye has a neutral stance on Episurf Medical’s Q2 report as sales have yet to take off. However, we see that its customer base is expanding nicely, and we argue that the most interesting news relates to its changed strategy. We will return with a case review update in which we dive deeper into the implications on the case.

Redeye has a neutral stance on Episurf Medical’s Q2 report as sales have yet to take off. However, we see that its customer base is expanding nicely, and we argue that the most interesting news relates to its changed strategy. We will return with a case review update in which we dive deeper into the implications on the case.
Börsvärldens nyhetsbrev
ANNONSER